P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000969064.86312.d3 |
| _version_ | 1797280137778036736 |
|---|---|
| author | Lijuan Hu Wei-LI Zhao Wen Wu Xudong Wei Ruihua MI Yu Hu Qiubai LI Wenjuan He Juan LI Yugang Dong Hehua Wang Xuhan Zhang Yu Zhang Zhongyuan Xu Hui Liu Zhen Cai Jie Sun Yajing Xu Zhiping Jiang Cheng Zhang Guo Chen Tiejun Gong Qinghua Tang Hongmei Jing Lan MA Sujun Gao Qiqi Liu Zeyu Zhong Yongxin Ren Jian Chen Songhua Fan Michael Shi Weiguo Su Xiaojun Huang |
| author_facet | Lijuan Hu Wei-LI Zhao Wen Wu Xudong Wei Ruihua MI Yu Hu Qiubai LI Wenjuan He Juan LI Yugang Dong Hehua Wang Xuhan Zhang Yu Zhang Zhongyuan Xu Hui Liu Zhen Cai Jie Sun Yajing Xu Zhiping Jiang Cheng Zhang Guo Chen Tiejun Gong Qinghua Tang Hongmei Jing Lan MA Sujun Gao Qiqi Liu Zeyu Zhong Yongxin Ren Jian Chen Songhua Fan Michael Shi Weiguo Su Xiaojun Huang |
| author_sort | Lijuan Hu |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:36:53Z |
| format | Article |
| id | doaj.art-ee9e9aa792c744dbbcafc05da152aad4 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:36:53Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-ee9e9aa792c744dbbcafc05da152aad42024-03-03T09:43:32ZengWileyHemaSphere2572-92412023-08-017e86312d310.1097/01.HS9.0000969064.86312.d3202308003-00440P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONSLijuan Hu0Wei-LI Zhao1Wen Wu2Xudong Wei3Ruihua MI4Yu Hu5Qiubai LI6Wenjuan He7Juan LI8Yugang Dong9Hehua Wang10Xuhan Zhang11Yu Zhang12Zhongyuan Xu13Hui Liu14Zhen Cai15Jie Sun16Yajing Xu17Zhiping Jiang18Cheng Zhang19Guo Chen20Tiejun Gong21Qinghua Tang22Hongmei Jing23Lan MA24Sujun Gao25Qiqi Liu26Zeyu Zhong27Yongxin Ren28Jian Chen29Songhua Fan30Michael Shi31Weiguo Su32Xiaojun Huang331 Peking University People’s Hospital, Beijing, China2 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China2 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China3 Henan Cancer Hospital, Zhengzhou, China3 Henan Cancer Hospital, Zhengzhou, China4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China5 The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China5 The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China5 The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China6 The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China7 Southern Medical University Nanfang Hospital, Guangzhou, China7 Southern Medical University Nanfang Hospital, Guangzhou, China7 Southern Medical University Nanfang Hospital, Guangzhou, China8 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China8 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China9 Xiangya Hospital Central South University, Changsha, China9 Xiangya Hospital Central South University, Changsha, China10 The Second Affiliated Hospital of Army Medical University of PLA, Chongqing, China10 The Second Affiliated Hospital of Army Medical University of PLA, Chongqing, China11 Harbin First Hospital Hematological Cancer Research Center, Harbin, China11 Harbin First Hospital Hematological Cancer Research Center, Harbin, China12 Peking University Third Hospital, Beijing, China12 Peking University Third Hospital, Beijing, China13 The First Hospital of Jilin University, Changchun, China14 HUTCHMED Limited, Shanghai, China14 HUTCHMED Limited, Shanghai, China14 HUTCHMED Limited, Shanghai, China14 HUTCHMED Limited, Shanghai, China14 HUTCHMED Limited, Shanghai, China14 HUTCHMED Limited, Shanghai, China14 HUTCHMED Limited, Shanghai, China1 Peking University People’s Hospital, Beijing, Chinahttp://journals.lww.com/10.1097/01.HS9.0000969064.86312.d3 |
| spellingShingle | Lijuan Hu Wei-LI Zhao Wen Wu Xudong Wei Ruihua MI Yu Hu Qiubai LI Wenjuan He Juan LI Yugang Dong Hehua Wang Xuhan Zhang Yu Zhang Zhongyuan Xu Hui Liu Zhen Cai Jie Sun Yajing Xu Zhiping Jiang Cheng Zhang Guo Chen Tiejun Gong Qinghua Tang Hongmei Jing Lan MA Sujun Gao Qiqi Liu Zeyu Zhong Yongxin Ren Jian Chen Songhua Fan Michael Shi Weiguo Su Xiaojun Huang P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS HemaSphere |
| title | P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS |
| title_full | P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS |
| title_fullStr | P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS |
| title_full_unstemmed | P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS |
| title_short | P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS |
| title_sort | p539 a phase 1 study of hmpl 306 a dual inhibitor of mutant isocitrate dehydrogenase idh 1 and 2 in pts with relapsed refractory myeloid hematological malignancies harboring idh1 and or 2 mutations |
| url | http://journals.lww.com/10.1097/01.HS9.0000969064.86312.d3 |
| work_keys_str_mv | AT lijuanhu p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT weilizhao p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT wenwu p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT xudongwei p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT ruihuami p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT yuhu p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT qiubaili p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT wenjuanhe p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT juanli p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT yugangdong p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT hehuawang p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT xuhanzhang p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT yuzhang p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT zhongyuanxu p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT huiliu p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT zhencai p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT jiesun p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT yajingxu p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT zhipingjiang p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT chengzhang p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT guochen p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT tiejungong p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT qinghuatang p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT hongmeijing p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT lanma p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT sujungao p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT qiqiliu p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT zeyuzhong p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT yongxinren p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT jianchen p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT songhuafan p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT michaelshi p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT weiguosu p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT xiaojunhuang p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations |